Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn pyrrolidone carboxylic acid
learn Pronalen Fibro-Actif
learn TRIOXIDIL®
Research
5 / 84 results
research Minoxidil-Induced Pleuro-Pericardial Effusion With Tamponade
Stopping minoxidil and draining fluid around the heart can save lives in rare cases.
research Pleuropericardial effusion associated with minoxidil administration
Minoxidil can cause pericardial and pleural effusions with high protein content.
research Atypical Case of Minoxidil-Induced Generalized Anasarca and Pleuropericardial Effusion
Minoxidil can cause severe body swelling and fluid buildup, which improves after stopping the drug and using diuretics.
research Eosinophilic Pleuropericardial Effusion due to Valproic Acid
Valproic acid can cause a rare allergic reaction leading to fluid around the lungs and heart, which is treatable by changing medication.
research MINOXIDIL INDUCED PLEURO-PERICARDIAL EFFUSION IN END-STAGE RENAL DISEASE
Community Join
5 / 1000+ resultscommunity Just find a cure already, I am totally done
The conversation is about hair loss treatments, with users recommending finasteride and minoxidil as effective solutions. Some users report side effects, but overall, the consensus is to use these treatments rather than waiting for a cure.
community RU-58841 Lung Disease Possibility | Chest pain, "heart issues", etc
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
community No sides with Ru58841 mixed with stemoxydine, yet sides mixed with fluridil
User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.
community RU58841 - Side Effects - Day 4: Chest Pain & Tightness, Bloodshot Eyes and some sort of inflammation/irritation on my throat.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.